You are here: Industry Insights > SII

News List

SII expects WHO emergency nod for AstraZeneca – Oxford University vaccine soon expresspharma
January 15, 2021
Poonawalla also said his company would start stockpiling millions of doses of the Novavax coronavirus vaccine candidate from around April.
SII receives purchase order from Government of India for 11 million doses of Covishield expresspharma
January 12, 2021
The government placed a purchase order with Serum Institute of India (SII) for 11 million doses of Oxford COVID-19 vaccine, Covishield, each dose costing Rs 210 including GST, official sources said.
SII, Bharat Biotech jointly pledge to work for smooth roll out of COVID-19 vaccines expresspharma
January 06, 2021
They said that the important task in front of them is saving the lives and livelihoods of populations in India and the world.
Concerns raised over India’s approval of COVID-19 vaccine with incomplete data europeanpharmaceuticalreview
January 05, 2021
The All India Drug Action Network has said it is “shocked” India has given approval to Covaxin, a COVID-19 vaccine with a lack of peer reviewed safety and efficacy data.
Awaiting India’s approval for COVISHIELD: SII expresspharma
December 31, 2020
The company made this statement after UK's approval of the Oxford-AstraZeneca COVID-19 vaccine.
SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech expresspharma
December 31, 2020
The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation (CDSCO) met on December 30, 2020, in the afternoon to consider the Emergency Use Authorisation (EUA) requests of Pfizer, Serum Institute of India (SII) and ...
DCGI probe finds no adverse event linked to SII’s Covid-19 vaccine pharmaceutical-technology
December 04, 2020
The Drugs Controller General of India’s (DCGI) probe found that an alleged serious adverse event (SAE) suffered by a volunteer in Covid-19 vaccine trial of Serum Institute of India (SII) in Chennai was unrelated to the shot he received.
PM to visit Serum Institute of India in Pune on Nov 28 expresspharma
November 27, 2020
The CDSCO has granted permission for manufacture of COVID-19 vaccine for pre-clinical test, examination and analysis to seven firms.
Covishield should be available for public by April 2021: Adar Poonawalla expresspharma
November 20, 2020
SII to make about 10 crore doses per month from February, 30-40 crore doses of the vaccine will be available by the first quarter of 2021.
IMCR and SII collaborate to develop Novavax’s Covid-19 vaccine in India pharmaceutical-technology
November 13, 2020
Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) have collaborated for clinical development of the Covid-19 vaccine, COVOVAX, by US-based firm Novavax and upscaled by SII.

Previous page 1 2 3 4 5 6 Next page